First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Q3 2025 Management View Stéphane Bancel, CEO, reported third quarter revenue of $1 billion, driven by sales of fully approved vaccines including Spikevax, mNEXSPIKE, and mRESVIA, and announced a net ...

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell ...

Hundreds of Boston residents and some Boston University students who ended up in the emergency room with the norovirus this winter may take comfort in a recent research breakthrough that may help ...

With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...

Moderna's mRNA-1273 vaccine helped prevent medically attended COVID-19 and related hospitalizations across multiple respiratory seasons among adults.

New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.

The team used the AMG1541 LNP to deliver an mRNA influenza vaccine in mice. They compared this vaccine’s effectiveness to a flu vaccine made with the lipid SM-102, which is FDA-approved and was used ...